Advertisement · 728 × 90
#
Hashtag
#NSABP
Advertisement · 728 × 90
GBG
GBG
@gbg.de
3 months ago
Post image Post image

At #SABCS2025, new translational results from the #NSABP B-59/GBG-96- #GeparDouze trial were presented by Carsten Denkert, highlighting how #TIL levels and molecular #TNBC subtypes shape response to #neoadjuvant immune-chemotherapy.

➡️ Full details are available here:
www.gbg.de/news/detail/...

1 0 0 0
GBG
GBG
@gbg.de
3 months ago
Post image

🧬 #SABCS2025 | Impact of Checkpoint Inhibition on Fertility in Young Women with Early TNBC

Key Findings from the #NSABP B-59/GBG-96-GeparDouze Substudy presented by Mattea Reinisch

➡️ For more details and the full presentation, please visit the #GBG website:
www.gbg.de/news/detail/...

#GeparDouze

0 0 0 0
GBG
GBG
@gbg.de
1 year ago
Foto of the cover slide during presentation: "NSABP B-59/GBG-96-GeparDouze: A randomized double-blind Phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant therapy."

Foto of the cover slide during presentation: "NSABP B-59/GBG-96-GeparDouze: A randomized double-blind Phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant therapy."

#NSABP B-59/GBG-96 #GeparDouze Phase III Trial presented at the #SABCS24 by Dr. Charles Geyer, Jr.
While the study did not meet its primary endpoint, the findings highlight the need for correlative biomarker studies to identify subsets of TNBC patients.

1 0 1 0